BridgeBio Pharma Inc (BBIO) concluded trading on Thursday at a closing price of $34.85, with 5.23 million shares of worth about $182.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 38.29% during that period and on May 08, 2025 the price saw a loss of about -2.71%. Currently the company’s common shares owned by public are about 189.83M shares, out of which, 174.48M shares are available for trading.
Stock saw a price change of -9.24% in past 5 days and over the past one month there was a price change of 15.63%. Year-to-date (YTD), BBIO shares are showing a performance of 27.00% which increased to 24.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.62 but also hit the highest price of $39.54 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 3.19 million. The stock is currently trading -2.06% below its 20-day simple moving average (SMA20), while that difference is up 1.41% for SMA50 and it goes to 18.16% higher than SMA200.
BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 189.83M outstanding shares and institutions hold larger chunk of about 76.99% of that.
The stock has a current market capitalization of $6.62B and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$3.53 in the same period. It has Quick Ratio of 4.54. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 4.02% while standing at 5.09% over the month.
Stock’s fiscal year EPS is expected to drop by -8.28% while it is estimated to increase by 35.99% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Redburn Atlantic on March 31, 2025 offering a Buy rating for the stock and assigned a target price of $50 to it. On October 03, 2024, Oppenheimer Initiated their recommendations, while on September 04, 2024, Piper Sandler Initiated their ratings for the stock with a price target of $46. Stock get an Outperform rating from Raymond James on March 21, 2024.
